Drug intelligence / Profile preview

COVIGEN C19

Development stage: Unknown
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

COVIGEN C19 is an investigational DNA-based vaccine developed to protect against infection with the SARS-CoV-2 virus, which causes COVID-19. As a DNA vaccine, it works by introducing genetic material encoding antigens from the virus into host cells, prompting an immune response that can recognize and fight off future infections. The primary indication for this vaccine is prevention of COVID-19. Clinical trials have been conducted to evaluate its safety and immunogenicity[1].

Brand names: COVIGEN C19

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on COVIGEN C19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIGEN C19.

Explore the full profile